Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Adam Wieschhaus
AddedMar 31, 2024
UpdatedMay 31, 2026
Adam Wieschhaus

Adam Wieschhaus

Board Member, Torus Biosystems

CrunchbaseLinkedIn

Adam Wieschhaus's Career

Torus Biosystems
Torus Biosystems

Medford, MA, US

Board Member· Board
Kytopen
Kytopen

Cambridge, MA, US

Board Member· Board
Slingshot Biosciences
Slingshot Biosciences

Emeryville, CA, US

Board Member· Board
Ultivue
Ultivue

Cambridge, MA, US

Board Member· Board
Vestaron
Vestaron

Kalamazoo, MI, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Adam Wieschhaus's Career

Torus Biosystems
Torus Biosystems
Series A$26.5M392019Medford, MA, US
Board Member· Board

Leadership at Torus Biosystems

Nancy HillNancy HillBoard Member
David ZhangDavid ZhangCo-Founder & CEO
Shawn MarcellShawn MarcellCo-Founder
Kytopen
Kytopen
Series A$37.1M172017Cambridge, MA, US
Board Member· Board

Leadership at Kytopen

Theresa TribbleTheresa TribbleBoard Member
Cullen BuieCullen BuieCo-Founder
Paulo A. Garcia, Ph.D.Paulo A. Garcia, Ph.D.Co-Founder
Slingshot Biosciences
Slingshot Biosciences

Emeryville, CA, US

Board Member· Board
Ultivue
Ultivue
Series D$107.3M562015Cambridge, MA, US
Board Member· Board

Leadership at Ultivue

Fenel EloiFenel EloiBoard Member
Ralf JungmannRalf JungmannCo-Founder
Keith CrandellKeith CrandellBoard Member
David WaltDavid WaltCo-Founder
Peng YinPeng YinCo-Founder
Martin MadausMartin MadausBoard Member

Similar to Ultivue

Altos LabsAltos LabsRedwood City, CA, USCell Therapiesest. 2021Altos LabsRedwood City, CA, US · est. 2021

Altos Labs, Inc.: An American biotech firm pioneering life extension therapies via specialized cell therapies since 2022.

Series A · $3B500
Zinnia TechnologiesZinnia TechnologiesChicago, IL, USCare Toolsest. 2019Zinnia TechnologiesChicago, IL, US · est. 2019

Zinnia Technologies: A leading care tool provider, offering rewarding careers and a balanced work-life culture.

Pre-Seed · $120k6
Upstream BioUpstream BioWaltham, MA, USAntibody Therapyest. 2021Upstream BioWaltham, MA, US · est. 2021

Upstream Bio: Clinical-stage developer of monoclonal antibody therapy for severe asthma.

Series B · $408M17
Vestaron
Vestaron

Kalamazoo, MI, US

Board Member· Board

Adam Wieschhaus's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Adam Wieschhaus

Francesco WiedemannFrancesco WiedemannFounder · KyteNikolaus VolkNikolaus VolkCEO · KyteAdrian BialonczykAdrian BialonczykFounder · Algo DepthThomas HuThomas HuFounder · Kyber CapitalMichael NowotnyMichael NowotnyFounder · Krypton